Andere Sprachen Lotus Pharmaceutical Co., Ltd.

Aktien

1795

TW0001795003

1795

Schlusskurs Taiwan S.E. Andere Börsenplätze 00:00:00 05.07.2024			% 5 Tage	% 1. Jan.
306,5 ^TWD	+0,99 %		-0,97 %	+12,68 %

27.06.	Nrx Pharmaceuticals, Inc. erhält eine Mitteilung über die Beendigung des exklusiven, globalen ? Entwicklungs-, Liefer-, Marketing- und Lizenzvereinbarung von und zwischen Alvogen, Inc., Alvogen Pharma Us, Inc. und Lotus Pharmaceutical Co. Ltd	CI
13.06.	Lotus Pharmaceutical Co. Ltd. kündigt Änderungen im Prüfungs- und Vergütungsausschuss an	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Nrx Pharmaceuticals, Inc. Receives A Notice of Termination of Exclusive, Global ? Development, Supply, Marketing & License Agreement by and Between Alvogen, Inc., Alvogen Pharma Us, Inc. and Lotus Pharmaceutical Co. Ltd	27.06.
Lotus Pharmaceutical Co., Ltd. Announces Audit and Remuneration Committee Changes	13.06.
Lotus Pharmaceutical Co., Ltd. Announces Board Changes	13.06.
Lotus International Pte. Ltd and Lotus Pharmaceutical Co., Ltd. agreed to acquire Teva Pharma Co., Ltd. from Actavis Group PTC ehf., Actavis Holding Asia BV and Actavis Dutch Holding B.V. for TWD 1.5 billion.	06.06.
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	11.05.
Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director	26.03.
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	14.03.
Lotus Pharmaceutical Co., Ltd. Announces the Appointment of Valerie Lau as APAC Chief Commercial Officer, Effective February 15, 2024	31.01.
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15.01.
Lotus Reported Unaudited December Consolidated Revenues of NT$1,372 million, showcasing MoM and YoY Growth 2023 Unaudited Consolidated Revenues Grew 16% to NT$16,958 million, marking 5th consecutive year of double-digit growth	11.01.
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09.11.
Lotus Pharmaceutical Co., Ltd. Reports Solid Financial Results for September 2023 and Year-to-Date Growth	12.10.23
Alvogen Korea Holdings Ltd. announced that it expects to receive KRW 29.51962949 billion in funding from Lotus Pharmaceutical Co., Ltd.	25.09.23
Lotus Pharmaceutical Co., Ltd. Announces Director Changes	04.09.23
Lotus Pharmaceutical Co., Ltd. and Fuji Pharma Co., Ltd. Joint Product Receives the Approval for Lenalidomide Capsules,2.5 Mg and 5 Mg from the Japan Pmda	15.08.23
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11.08.23
Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across Asia	10.08.23
LOTUS PHARMACEUTICAL AND AMARIN CORPORATION PLC ANNOUNCE EXCLUSIVE PARTNERSHIP AGREEMENT TO COMMERCIALIZE VAZKEPA IN SOUTHEAST ASIA AND SOUTH KOREA	02.08.23
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea	31.07.23
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Taiwan	12.07.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Lotus Pharmaceutical Co., Ltd.

Aktien

1795

TW0001795003

1795

Andere Sprachen

Filter